アブストラクト
| Title | 片頭痛の新規薬物療法 |
|---|---|
| Subtitle | 特集 見逃せない痛みと根拠がわかる 頭痛薬の使い方 [一次性頭痛の治療] |
| Authors | 柴田護 |
| Authors (kana) | |
| Organization | 東京歯科大学市川総合病院神経内科 |
| Journal | 月刊薬事 |
| Volume | 63 |
| Number | 11 |
| Page | 2251-2256 |
| Year/Month | 2021 / 8 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ■急性期治療では, セロトニン5-HT1B/1D/1F受容体作動薬のトリプタン製剤が主に用いられているが, 血管収縮作用が問題になることがある. 選択的5-HT1F受容体作動薬やカルシトニン遺伝子関連ペプチド (CGRP) 受容体拮抗薬は血管収縮作用のない急性期治療薬として注目されている. ■発作予防治療では, カルシウム拮抗薬や抗てんかん薬などが経験的に用いられてきたが, CGRPあるいはCGRP受容体に対するモノクローナル抗体がすでに臨床応用に至っている. ■CGRP受容体拮抗薬も発作予防薬としての開発が進められている. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) GBD 2016 Disease and Injury Incidence and Prevalence Collaborators : Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390 : 1211-1259, 2017
- 2) Mecklenburg J, et al : The potential of lasmiditan in migraine. Ther Adv Neurol Disord, 13 : 1756286420967847, 2020
- 3) Kuca B, et al : Lasmiditan is an effective acute treatment for migraine : A phase 3 randomized study. Neurology, 91 : e2222-e2232, 2018
- 4) Goadsby PJ, et al : Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain, 142 : 1894-1904, 2019
- 5) Brandes JL, et al : Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine(the GLADIATOR study). Cephalalgia, 39 : 1343-1357, 2019
残りの23件を表示する
- 6) Moreno-Ajona D, et al : Gepants, calcitonin-gene-related peptide receptor antagonists : what could be their role in migraine treatment? Curr Opin Neurol, 33 : 309-315, 2020
- 7) Dodick DW, et al : Ubrogepant for the treatment of migraine, N Engl J Med, 381 : 2230-2241, 2019
- 8) Lipton RB, et al : Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med, 381 : 142-149, 2019
- 9) 柴田 護 : CGRP関連抗体による片頭痛の新規治療. 臨床神経学, 60 : 668-676, 2020
- 10) Dodick DW : CGRP ligand and receptor monoclonal antibodies for migraine prevention : Evidence review and clinical impli-cations. Cephalalgia, 39 : 445-458, 2019
- 11) Stauffer VL, et al : Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial. JAMA Neurol, 75 : 1080-1088, 2018
- 12) Skljarevski V, et al : Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia, 38 : 1442-1454, 2018
- 13) Detke HC, et al : Rapid onset of effect of galcanezumab for the prevention of episodic migraine : analysis of the EVOLVE studies. Headache, 60 : 348-359, 2020
- 14) Sakai F, et al : Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : A phase 2 randomized controlled clinical trial. Cephalalgia Reports, 3 : 251581632093257, 2020
- 15) Shibata M, et al : Migraine-specific quality-of-life question-naire(MSQ)version 2.1 score improvement in Japanese patients with episodic migraine by galcanezumab treatment : Japan phase 2 study. J Pain Res, 13 : 3531-3538, 2020
- 16) Dodick DW, et al : Effect of fremanezumab compared with placebo for prevention of episodic migraine : A randomized clinical trial. JAMA, 319 : 1999-2008, 2018
- 17) Silberstein SD, et al : Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med, 377 : 2113-2122, 2017
- 18) Goadsby PJ, et al : A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med, 377 : 2123-2132, 2017
- 19) Goadsby PJ, et al : One-year sustained efficacy of erenumab in episodic migraine : results of the STRIVE study. Neurology, 95 : e469-e479, 2020
- 20) Dodick DW, et al : ARISE : A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia, 38 : 1026-1037, 2018
- 21) Sakai F, et al : A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache, 59 : 1731-1742, 2019
- 22) Tepper S, et al : Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol, 16 : 425-434, 2017
- 23) Tepper SJ, et al : Erenumab in chronic migraine with medication overuse : subgroup analysis of a randomized trial. Neurology, 92 : e2309-e2320, 2019
- 24) Mullin K, et al : Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology, 94 : e2121-e2125, 2020
- 25) Ashina M, et al : Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study(PROMISE-1). Cephalalgia, 40 : 241-254, 2020
- 26) Lipton RB, et al : Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2. Neurology, 94 : e1365-e1377, 2020
- 27) Croop R, et al : Oral rimegepant for preventive treatment of migraine : a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet, 397 : 51-60, 2021
- 28) Goadsby PJ, et al : Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults : a double-blind, randomised phase 2b/3 trial. Lancet Neurol, 19 : 727-737, 2020
